Luis Gutierrez
Psychiatry · Bradenton, FLNPI 1801882022
Payments from drug & device makers
Across 199 payments — averaging $24.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$805
- Teva Pharmaceuticals USA, Inc.$787
- Sunovion Pharmaceuticals Inc.$524
- AbbVie$518
- Alkermes, Inc.$508
- plus $481 from 5 others
What the payments were for
- Food & beverage$4,824100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $1,202 |
| Johnson & Johnson | 17 | $805 |
| Teva Pharmaceuticals USA, Inc. | 49 | $787 |
| Sunovion Pharmaceuticals Inc. | 26 | $524 |
| AbbVie(2 entities) | 23 | $518 |
| Alkermes, Inc. | 26 | $508 |
| Neurocrine Biosciences, Inc. | 13 | $380 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Indivior Inc. | 2 | $27 |
| Zimmer Biomet | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$366
- ABILIFY MAINTENA$338
- LATUDA$246
- SPRAVATO$230
- AUSTEDO$215
- INGREZZA$125
- INVEGA SUSTENNA$124
- INVEGA TRINZA$124
How this compares
$4,824 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 182 | $576,564 |
| Abilify MaintenaAripiprazole | 71 | $204,985 |
| Austedo XrDeutetrabenazine | 34 | $201,451 |
| Invega TrinzaPaliperidone Palmitate | 26 | $182,551 |
| CaplytaLumateperone Tosylate | 54 | $87,801 |
| Olanzapine | 168 | $11,975 |
| Aripiprazole | 52 | $10,227 |
| Fluphenazine Hcl | 44 | $6,286 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $6,249 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 31 | $5,941 |
| Lurasidone Hcl | 61 | $5,244 |
| Quetiapine Fumarate | 101 | $2,571 |
| Hydroxyzine Pamoate | 59 | $1,307 |
| Haloperidol | 31 | $1,271 |
| Haloperidol Decanoate | 33 | $1,187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $805 | $759,115208 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,202 | $204,98571 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $787 | $201,45134 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $34 | $87,80154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Bradenton
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.